eLetters

359 e-Letters

  • Response to Dr Yazici's eLetter: Ethical issue of withholding treatment from patients with active rheumatoid arthritis
    Tsutomu Takeuchi

    Dear Editor,

    The ethical consideration in placebo-controlled studies of antirheumatic drugs is of primary importance. We thank Dr Yazici for his questions regarding the ethical aspect of our study.

    The GO-MONO study was designed to have placebo crossover to methotrexate (MTX) at Week 16, as a Registration Study to Japan Health Authority, following the MHLW Guideline for the Clinical Study and Evaluat...

    Show More
  • Diagnosing Erdheim-Chester Disease
    Lorenzo Dagna

    Dear Editor,

    Although we generally agree with Dr Juanos-Iborra et al [1] who noted that some of the most common manifestations of Erdheim-Chester disease (ECD) at time of onset (such as skeletal, constitutional or even neurological symptoms) may lack adequate specificity for a timely and prompt diagnosis, it is conceivable that the same manifestations, if unexplained, may often lead to further imaging and histologic...

    Show More
  • Response to 'In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis' by Kortekaas et al
    Dr Ai Lyn Tan

    We read with interest the article 'In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis' by Kortekaas et al [1]. The authors found that interphalangeal joints of erosive osteoarthritis (EOA) patients, with erosions being defined by conventional radiography (CR), demonstrated more sonographic inflammatory changes in adjacent non CR-eroded joints compared to...

    Show More
  • Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as anti-nuclear antibodies
    Michael Mahler

    Dear Editor,

    Despite significant efforts and advances in the field of autoimmune diagnostics, the standardization and proper use of antinuclear antibody (ANA) testing in clinical practice remains a challenge. In 2013, important contributions attempting to clarify and add rigor to this area have been published [1, 2]. In particular, the recent recommendations published by Agmon-Levin et al. [1] address very impo...

    Show More
  • Response to Gonzalez-Gay's eLetter on Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
    Michael T Nurmohamed

    Dear Editor,

    In their comments about our systematic review on cardiovascular (CV) comorbidities in patients with psoriatic arthritis, (1) dr Gonzalez-Gay and colleagues, point out that in their studies, (2,3) in contrast to our Table 4, they did demonstrate a correlation between inflammatory parameters and flow-mediated dilatation (FMD) or intima media thickness (IMT). This is indeed correct when these tests are c...

    Show More
  • Re:Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?
    Frank van den Hoogen

    Dear Editor

    In his letter, Jan Damoiseaux plees for testing of anti-RNA polymerase III antibodies (ARA), and also other (novel) SSc-associated antibodies, only for those patients who are really suspected for SSc. Damoiseaux argues that there is a necessity to provide clinical information together with the request for testing for rheumatic systemic autoimmune diseases.

    We very much agree that testing for S...

    Show More
  • Response
    Gianfranco Ferraccioli

    Dear Editor,

    We thank Aramugakani et al. for their critical reading of our Editorial (1) accompanying Cheng et al. paper on the role of long-lived plasma cells (PC) in driving murine lupus nephritis (LN) (2). First, we obviously share - and explicitely mentioned - the safety issues related to long-lived PC depletion, in particular a possible high infection rate. Second, our purpose was not to question the effe...

    Show More
  • Response to H Zeidler's comments on the INFAST study
    Joachim Sieper

    Dear Editor,

    In his comments about our INFAST trial (1) H Zeidler addresses the question whether a separation in patients with predominant axial and with predominant peripheral spondyloarthritis (SpA) manifestations makes sense and whether it reflects realitiy. Peripheral arthritis is one of the clinical parameters used in the classification criteria for axial (ax) SpA (2). However, it is not used here as an activ...

    Show More
  • Re: Paying attention to arbitrary causality and the preciseness of conclusion
    Changhai Ding

    Dear Editor,

    We would like to thank Dr. Lei for the comments on our paper. Please see the point-to-point response as below:

    1. As pointed out in the discussion of our paper, cross-sectional and case-control designs are not able to infer a causal relationship. The conclusion 'low grade systemic inflammation may play a greater role in symptoms rather than radiographic changes in OA' does not necessarily...

    Show More
  • Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?
    Jan Damoiseaux

    Dear Editor,

    Recently a collaborative initiative of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) resulted in novel classification criteria for systemic sclerosis (SSc) [1]. These criteria were first selected in a derivation cohort and, next, confirmed in a validation cohort. From a laboratory perspective it is interesting that the new criteria include, besides th...

    Show More

Pages